# Perioperative Management of Anticoagulation and Antiplatelet Therapy

## Introduction

Managing anticoagulation and antiplatelet therapy in the perioperative period is one of the most common and consequential clinical decisions in neurosurgery. The neurosurgeon must balance the risk of thromboembolic events from withholding these medications against the risk of surgical hemorrhage from continuing them. Given the catastrophic consequences of intracranial bleeding, neurosurgical procedures generally demand more stringent hemostatic control than other surgical disciplines.

## Coagulation Cascade Review

The coagulation cascade consists of two converging pathways. The intrinsic pathway involves factors XII, XI, IX, and VIII and is assessed by the aPTT. The extrinsic pathway involves tissue factor and factor VII and is assessed by the PT/INR. Both converge on the common pathway, where factors X, V, and II (prothrombin) along with fibrinogen drive thrombin generation and fibrin clot formation. Equally critical for primary hemostasis is platelet function: adhesion occurs via von Willebrand factor, activation is mediated by thromboxane A2 and ADP, and aggregation depends on GPIIb/IIIa receptors.

## Anticoagulant Medications

### Warfarin

Warfarin is a vitamin K antagonist that inhibits factors II, VII, IX, and X as well as proteins C and S. It is monitored by the INR, with a therapeutic range typically of 2.0 to 3.0. Its half-life is 36 to 42 hours, and full clearance of its effect requires 5 to 7 days after discontinuation. Reversal options include vitamin K given IV with an onset of 6 to 24 hours, fresh frozen plasma (FFP), and 4-factor prothrombin complex concentrate (4F-PCC), which is preferred for urgent reversal due to its speed.

### Direct Oral Anticoagulants (DOACs)

The DOACs include dabigatran (Pradaxa), a direct thrombin inhibitor with a half-life of 12 to 17 hours, and the factor Xa inhibitors rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa), with half-lives of 5 to 12 hours. These agents are not reliably monitored by standard coagulation tests, though anti-Xa levels can assess the factor Xa inhibitors. Specific reversal agents are available: idarucizumab (Praxbind) reverses dabigatran, and andexanet alfa (Andexxa) reverses factor Xa inhibitors. When specific agents are unavailable, 4F-PCC serves as an alternative.

| Agent | Mechanism | Half-Life | Monitoring | Reversal |
|-------|-----------|-----------|------------|----------|
| Warfarin | Vitamin K antagonist (II, VII, IX, X) | 36-42 h | INR | Vitamin K, FFP, 4F-PCC |
| Dabigatran | Direct thrombin inhibitor | 12-17 h | Thrombin time (unreliable standard tests) | Idarucizumab |
| Rivaroxaban | Factor Xa inhibitor | 5-9 h | Anti-Xa level | Andexanet alfa; 4F-PCC |
| Apixaban | Factor Xa inhibitor | 8-12 h | Anti-Xa level | Andexanet alfa; 4F-PCC |
| UFH | Antithrombin potentiator | 60-90 min | aPTT | Protamine sulfate |
| LMWH | Antithrombin potentiator (Xa > IIa) | 4-6 h | Anti-Xa level | Protamine (partial) |
| Aspirin | COX-1 inhibitor | Platelet lifetime (7-10 d) | Platelet function assay | Platelet transfusion |
| Clopidogrel | Irreversible P2Y12 inhibitor | Platelet lifetime | VerifyNow/TEG | Platelet transfusion |

### Heparin

Unfractionated heparin (UFH) is given IV, monitored by aPTT, has a half-life of 60 to 90 minutes, and is reversed with protamine sulfate. Low molecular weight heparin (LMWH), including enoxaparin and dalteparin, is given subcutaneously, monitored by anti-Xa levels, has a half-life of 4 to 6 hours, and is only partially reversed by protamine.

![Table summarizing anticoagulant medications with their mechanisms, monitoring parameters, half-lives, and reversal agents](/images/neurosurgery/anticoagulant-summary-table.png)

## Antiplatelet Medications

### Aspirin

Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), blocking thromboxane A2 synthesis. Its platelet effect lasts the lifetime of the platelet, which is 7 to 10 days. Low-dose aspirin at 81 mg may be continued for minor neurosurgical procedures in some protocols. There is no specific reversal agent, and platelet transfusion is used for life-threatening bleeding.

### P2Y12 Receptor Inhibitors

Clopidogrel (Plavix) is an irreversible inhibitor that should be discontinued 5 to 7 days before surgery. Prasugrel (Effient) is also irreversible but more potent and should be discontinued 7 to 10 days preoperatively. Ticagrelor (Brilinta) is a reversible inhibitor requiring discontinuation 3 to 5 days before surgery. Platelet function assays such as VerifyNow and TEG can assess the residual antiplatelet effect.

### GPIIb/IIIa Inhibitors

Abciximab, eptifibatide, and tirofiban are IV agents used in acute coronary syndromes and neurointerventional procedures. They have short half-lives measured in minutes to hours, and their effect wanes quickly after discontinuation, with the exception of abciximab, which persists for 12 to 24 hours.

## Preoperative Assessment and Planning

### Risk Stratification for Thromboembolism

High-risk patients include those with a mechanical heart valve (mitral position carrying higher risk than aortic), recent venous thromboembolism within three months, atrial fibrillation with a CHA2DS2-VASc score of 7 or greater, or a recent coronary stent (within six weeks for bare metal, within six months for drug-eluting). Moderate-risk patients include those with a bioprosthetic valve, VTE three to twelve months prior, or a CHA2DS2-VASc score of 5 to 6. Low-risk patients include those with atrial fibrillation and a CHA2DS2-VASc score of 1 to 4 or VTE more than twelve months prior.

### Risk Stratification for Surgical Bleeding

Neurosurgical procedures are generally classified as high bleeding risk. Intracranial hemorrhage within a closed space can be rapidly fatal, and even minor bleeding in the spinal canal can cause neurological deficit. The target INR for most intracranial procedures is 1.4 or less, with many surgeons preferring an INR below 1.2.

![Flowchart for perioperative anticoagulation management decision-making in neurosurgical patients](/images/neurosurgery/periop-anticoag-flowchart.png)

## Perioperative Protocols

### Warfarin Management

Warfarin should be discontinued five days before surgery. The INR is checked on the day of surgery, and the procedure proceeds if the INR is at or below 1.4. Bridging anticoagulation with LMWH or UFH is considered for high-risk patients. Therapeutic LMWH is started three days after stopping warfarin, with the last dose given 24 hours before surgery for therapeutic dosing or 12 hours for prophylactic dosing. LMWH is restarted 24 to 48 hours postoperatively once hemostasis is secure. The BRIDGE trial demonstrated that forgoing bridging was noninferior to bridging in atrial fibrillation patients undergoing elective procedures, with significantly fewer bleeding events, though neurosurgery patients were excluded from that trial.

### DOAC Management

DOACs should be discontinued 2 to 3 days before surgery for agents with normal renal clearance. Dabigatran requires an extended hold of 4 to 5 days if creatinine clearance is below 50 mL/min, as it is renally cleared. Bridging is typically not required due to the short half-lives and rapid onset of these agents upon resumption. DOACs are restarted 48 to 72 hours postoperatively depending on the bleeding risk assessment.

### Antiplatelet Management

For aspirin monotherapy, continuation may be considered for low-risk procedures such as VP shunt or spine hardware placement, while discontinuation 7 days before craniotomy is standard at many institutions. For patients on dual antiplatelet therapy (DAPT), the P2Y12 inhibitor should be discontinued 5 to 7 days before surgery, with aspirin potentially continued in consultation with cardiology. Coordination with cardiology is essential for coronary stent patients, as premature DAPT cessation risks stent thrombosis with a mortality rate of 20 to 40 percent. Elective surgery should be delayed beyond the mandatory DAPT period when possible.

## Emergency Neurosurgery on Anticoagulated Patients

For patients on warfarin, 4F-PCC at 25 to 50 units/kg is administered along with IV vitamin K 10 mg, and the INR is rechecked in 15 to 30 minutes. For dabigatran, idarucizumab 5 g IV is given, or if unavailable, 4F-PCC or hemodialysis is considered. For factor Xa inhibitors, andexanet alfa is given per dosing protocol, with 4F-PCC at 50 units/kg as an alternative. For antiplatelet agents, platelet transfusion is given though its efficacy is debated, and desmopressin (DDAVP) at 0.3 mcg/kg may augment platelet function. Life-saving surgery should not be delayed for complete reversal; the operation should proceed with the best available correction.

## Venous Thromboembolism Prophylaxis

Neurosurgical patients are at high risk for VTE due to brain tumors, prolonged immobility, and lower extremity weakness. Mechanical prophylaxis with sequential compression devices should be applied intraoperatively and continued until full ambulation. Chemical prophylaxis with LMWH (enoxaparin 40 mg subcutaneously daily) or UFH (5000 units subcutaneously every 8 to 12 hours) is typically initiated 24 to 48 hours postoperatively once hemostasis is confirmed on postoperative imaging. The risk of postoperative intracranial hemorrhage from chemical prophylaxis must be weighed against a VTE rate of 15 to 25 percent without chemoprophylaxis in craniotomy patients.

![Diagram of perioperative timeline showing when to stop and restart anticoagulant and antiplatelet medications relative to surgery](/images/neurosurgery/periop-medication-timeline.png)

## Clinical Pearls

Neurosurgery is a high bleeding risk specialty, and clinicians should err on the side of adequate hemostatic correction before elective procedures. Coordination with cardiology is mandatory for patients on DAPT after coronary stenting, as stent thrombosis is a life-threatening event. 4F-PCC is preferred over FFP for urgent warfarin reversal due to faster onset, smaller volume, and more predictable response. DOACs have short half-lives and generally do not require bridging, but clinicians must know the specific reversal agents for each. Mechanical VTE prophylaxis should be initiated on all neurosurgical patients, with transition to chemical prophylaxis 24 to 48 hours postoperatively once imaging confirms no hemorrhagic complications.

## References

1. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation (BRIDGE trial). *New England Journal of Medicine*. 2015;373(9):823-833.
2. Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage. *Neurocritical Care*. 2016;24(1):6-46.
3. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. *New England Journal of Medicine*. 2019;380(14):1326-1335.
4. Alshafai N, Mamdani M, Bhatt D, et al. Perioperative management of antithrombotic therapy in neurosurgical patients. *Journal of Neurosurgery*. 2021;134(4):1304-1314.